TY - T1的介入时机的重要性在博来霉素模型的肺纤维化JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.01105 -2019欧元SP - 1901105 AU -科尔布,菲利普盟——Upagupta Chandak盟——Vierhout梅根盟——Ayaub Ehab AU - Bellaye,皮埃尔西蒙盟——Gauldie杰克盟——ShimboriN2 -特发性肺纤维化(Idiopathic Pulmonary Fibrosis, IPF)是一种病因不明的复杂疾病，这使得药物开发具有挑战性。博莱霉素单次直接给小鼠肺是一种广泛使用的实验模型，用于研究肺纤维化和评估治疗抗纤维化策略的效果。该模型的工作原理是诱导早期炎症期，在5-7天后转变为纤维化。这种初始炎症使得治疗时机至关重要。为了准确评估抗纤维化疗效，干预应在不影响早期炎症的情况下抑制纤维化。从PubMed检索2008年至2019年发表的使用博莱霉素模型研究肺纤维化的研究，并分析研究特征。以干预为基础的研究分为预防性(使用博莱霉素后7天开始)和治疗性(使用博莱霉素后7天)。研究还与目前主要的临床试验进行交叉参考，以评估临床前合理用药的有效性。总共评价了976份出版物。726人调查了潜在的治疗方法，其中443人(61.0%)单独预防，166人(22.9%)单独治疗，105人(14.5%)两者都有。 Of the 443 preventative studies, only 70 (15.8%) characterised inflammation during the model's early inflammatory phase. Of the reported 145 IPF clinical trials investigating 93 compounds/combinations, only 25 (26.9.0%) had any PubMed-available preclinical data in bleomycin.Since 2008, we observed a shift (from <5% to 37.4%) in the number of studies evaluating drugs in the therapeutic setting in the bleomycin model. While this shift is encouraging, more characterisation of early inflammation and appropriate preclinical therapeutic testing are still needed. This will facilitate fruitful drug development in IPF, and more therapeutic strategies for patient with this devastating disease.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Upagupta has nothing to disclose.Conflict of interest: Dr. Ask reports grants from Boehringer Ingelheim, grants from GSK, grants from Prometic, grants from Alkermes, grants from Pharmaxis, grants from Respivert, grants from Indalo, grants from Canadian Institutes for Health Research, grants from Kniksa, grants from Avalyn, grants from National Sciences and Engineering Research Council, grants from Ontario Thoracic Society, grants from Candadian Pulmonary Fibrosis Foundation, grants from Actelion, grants from Gilead, grants from Patara, grants from Synairgen, grants from Unity, outside the submitted work.Conflict of interest: Dr. Ayaub has nothing to disclose.Conflict of interest: Dr. Kolb reports grants and personal fees from Roche, grants and personal fees from Boehringer Ingelheim, grants from GSK, grants from Respivert, personal fees from Genoa, grants from Alkermes, grants from Pharmaxis, grants and personal fees from Prometic, personal fees from Indalo, personal fees from Third Pole, personal fees from Pieris, grants from Canadian Institute for Health Research, outside the submitted work.Conflict of interest: Dr. Bellaye has nothing to disclose.Conflict of interest: Dr. Chiko Shimbori has nothing to disclose.Conflict of interest: Mr. Philipp Kolb has nothing to disclose.Conflict of interest: Dr. Gauldie has nothing to disclose.Conflict of interest: Miss Megan Vierhout has nothing to disclose.Conflict of interest: Dr. Inman has nothing to disclose. ER -